董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Elisha W. Finney | 女 | Director | 63 | 28.71万美元 | 0.03 | 2025-11-06 |
| Domitille Doat Le Bigot | 女 | Director | 52 | 26.91万美元 | 0.02 | 2025-11-06 |
| Wolfgang Wienand | 男 | Director | 53 | 27.06万美元 | 0.01 | 2025-11-06 |
| Pablo Perversi | -- | Independent Director | -- | 未披露 | 未持股 | 2025-11-06 |
| Michael A. Kelly | 男 | Director | 68 | 28.28万美元 | 0.17 | 2025-11-06 |
| Thomas P. Salice | 男 | Director | 65 | 33.74万美元 | 7.52 | 2025-11-06 |
| Brian Shepherd | 男 | Director | 58 | 22.21万美元 | 0.0083 | 2025-11-06 |
| Roland Diggelmann | 男 | Board Chair | 57 | 65.21万美元 | 0.06 | 2025-11-06 |
| Ingrid Zhang | 女 | Director | 52 | 26.91万美元 | 0.01 | 2025-11-06 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Patrick Kaltenbach | 男 | President and Chief Executive Officer | 61 | 681.76万美元 | 0.17 | 2025-11-06 |
| Shawn P. Vadala | 男 | Chief Financial Officer | 56 | 230.29万美元 | 0.48 | 2025-11-06 |
| Gerhard Keller | 男 | Head of Process Analytics | 57 | 134.04万美元 | 0.0006 | 2025-11-06 |
| Richard Wong | 男 | Head of Asia and Pacific | 60 | 118.68万美元 | 0.04 | 2025-11-06 |
| Marc de la Gueronniere | 男 | Head of European and North American Market Organizations | 61 | 168.14万美元 | 未持股 | 2025-11-06 |
| Christian Magloth | 男 | Head of Human Resources | 59 | 未披露 | 未持股 | 2025-11-06 |
| Roland Diggelmann | 男 | Board Chair | 57 | 65.21万美元 | 0.06 | 2025-11-06 |
董事简历
中英对照 | 中文 | 英文- Elisha W. Finney
-
Elisha W. Finney，自2017年11月起担任董事。她担任审计委员会主席。她拥有乔治亚大学风险管理和保险工商管理学士学位，金门大学工商管理硕士学位。Finney是NanoString Technologies，Inc.的董事和审计委员会主席，以及ICU Medical, Inc.和Viatris Inc.的董事，她是这两家公司的审计委员会成员。她此前曾担任Cutera，Inc.的董事至2019年6月，Irobot Corporation至2021年11月。Finney女士自1999年至2017年6月退休期间一直担任Varian医疗 Inc.的首席财务官。她于1988年加入Varian，在被任命为首席财务官之前曾担任过多种财务职务。
Elisha W. Finney,has been a director since November 2017. She serves as Chair of the Audit Committee. She has a Bachelor's of Business Administration in Risk Management and Insurance from the University of Georgia, and a Master's in Business Administration from Golden Gate University.Ms. Finney is a Director at ICU Medical, Inc. and Viatris Inc, where she is a member of the Audit Committee for both companies. She previously was a Director of Cutera, Inc. until June 2019, iRobot Corporation until November 2021, and NanoString Technologies, Inc. until June 2024.Ms. Finney was the Chief Financial Officer of Varian Medical Systems Inc. from 1999 until her retirement in June 2017. She joined Varian in 1988 and served in a variety of finance roles prior to her appointment as CFO. - Elisha W. Finney，自2017年11月起担任董事。她担任审计委员会主席。她拥有乔治亚大学风险管理和保险工商管理学士学位，金门大学工商管理硕士学位。Finney是NanoString Technologies，Inc.的董事和审计委员会主席，以及ICU Medical, Inc.和Viatris Inc.的董事，她是这两家公司的审计委员会成员。她此前曾担任Cutera，Inc.的董事至2019年6月，Irobot Corporation至2021年11月。Finney女士自1999年至2017年6月退休期间一直担任Varian医疗 Inc.的首席财务官。她于1988年加入Varian，在被任命为首席财务官之前曾担任过多种财务职务。
- Elisha W. Finney,has been a director since November 2017. She serves as Chair of the Audit Committee. She has a Bachelor's of Business Administration in Risk Management and Insurance from the University of Georgia, and a Master's in Business Administration from Golden Gate University.Ms. Finney is a Director at ICU Medical, Inc. and Viatris Inc, where she is a member of the Audit Committee for both companies. She previously was a Director of Cutera, Inc. until June 2019, iRobot Corporation until November 2021, and NanoString Technologies, Inc. until June 2024.Ms. Finney was the Chief Financial Officer of Varian Medical Systems Inc. from 1999 until her retirement in June 2017. She joined Varian in 1988 and served in a variety of finance roles prior to her appointment as CFO.
- Domitille Doat Le Bigot
-
Domitille Doat Le Bigot从2020年2月开始担任董事。她拥有ESSEC商学院和墨尔本商学院的工商管理硕士学位。 自2016年以来，她一直担任达能的首席数字官，并且是嘉士伯集团董事会成员。
Domitille Doat Le Bigot,has been a director since February 2020. She serves on the Nominating & Corporate Governance Committee. She has a Master's in Business Administration from the ESSEC Business School and the Melbourne Business School. She has been Chief Digital and Information Officer and a member of the Partners Committee at Eurazeo, since 2024. She joined Eurazeo in April 2021, and prior to her current role served as its Chief Digital Officer. She is currently a member of the Board of Directors at Gaztransport & Technigaz (GTT), and of the Advisory Digital Board at Carlsberg Group and until 2020 was a member of its board.Prior to her joining Eurazeo, Ms. Doat-Le Bigot served as Chief Digital Officer at Danone from 2016 to 2021, and from 2014 to 2016 she served as Deputy General Manager and Head of Technology and Data in Shanghai and Paris at Fred & Farid Group, an international independent digital agency. Prior to 2014 she served in creative management and digital production and design positions at Cisco and Ubisoft Entertainment. - Domitille Doat Le Bigot从2020年2月开始担任董事。她拥有ESSEC商学院和墨尔本商学院的工商管理硕士学位。 自2016年以来，她一直担任达能的首席数字官，并且是嘉士伯集团董事会成员。
- Domitille Doat Le Bigot,has been a director since February 2020. She serves on the Nominating & Corporate Governance Committee. She has a Master's in Business Administration from the ESSEC Business School and the Melbourne Business School. She has been Chief Digital and Information Officer and a member of the Partners Committee at Eurazeo, since 2024. She joined Eurazeo in April 2021, and prior to her current role served as its Chief Digital Officer. She is currently a member of the Board of Directors at Gaztransport & Technigaz (GTT), and of the Advisory Digital Board at Carlsberg Group and until 2020 was a member of its board.Prior to her joining Eurazeo, Ms. Doat-Le Bigot served as Chief Digital Officer at Danone from 2016 to 2021, and from 2014 to 2016 she served as Deputy General Manager and Head of Technology and Data in Shanghai and Paris at Fred & Farid Group, an international independent digital agency. Prior to 2014 she served in creative management and digital production and design positions at Cisco and Ubisoft Entertainment.
- Wolfgang Wienand
-
Wolfgang Wienand,Wienand博士是Siegfried Holding AG （SIX： SFZN）的首席执行官，Siegfried Holding AG是制药行业合同开发和制造（CDMO）的全球领导者。他于2010年加入Siegfried，担任执行委员会成员，最初担任首席科学官，然后担任首席战略官，后来在2019年成为首席执行官之前同时担任这两个职位。加入Siegfried之前，他曾担任Evonik Industries AG（全球领先的特种化学品公司）的高级管理职位。
Wolfgang Wienand,has been a director since November 2023. He serves on the Compensation Committee. Since July 2024, he is the Chief Executive Officer of Lonza Group Ltd., the world's largest contract development and manufacturing organization (CDMO) for the pharmaceutical industry. He studied chemistry at the University of Bonn and subsequently obtained a Ph.D. in organic and bioorganic chemistry from the University of Cologne. In addition, he holds an Executive Master's Degree in International Finance of cole des hautes études commerciales HEC Paris.From January 2019 until March 2024, Dr. Wienand served as CEO of Siegfried Holding AG, a globally leading CDMO for the pharmaceutical industry. He joined Siegfried in 2010, initially as Chief Scientific Officer, then as Chief Strategy Officer, before becoming CEO. Prior to Siegfried, Dr. Wienand held senior management positions at Evonik Industries AG, a leading global specialty chemicals company. Dr. Wienand served as a non-executive board member for SCHOTT Pharma until December 2024. - Wolfgang Wienand,Wienand博士是Siegfried Holding AG （SIX： SFZN）的首席执行官，Siegfried Holding AG是制药行业合同开发和制造（CDMO）的全球领导者。他于2010年加入Siegfried，担任执行委员会成员，最初担任首席科学官，然后担任首席战略官，后来在2019年成为首席执行官之前同时担任这两个职位。加入Siegfried之前，他曾担任Evonik Industries AG（全球领先的特种化学品公司）的高级管理职位。
- Wolfgang Wienand,has been a director since November 2023. He serves on the Compensation Committee. Since July 2024, he is the Chief Executive Officer of Lonza Group Ltd., the world's largest contract development and manufacturing organization (CDMO) for the pharmaceutical industry. He studied chemistry at the University of Bonn and subsequently obtained a Ph.D. in organic and bioorganic chemistry from the University of Cologne. In addition, he holds an Executive Master's Degree in International Finance of cole des hautes études commerciales HEC Paris.From January 2019 until March 2024, Dr. Wienand served as CEO of Siegfried Holding AG, a globally leading CDMO for the pharmaceutical industry. He joined Siegfried in 2010, initially as Chief Scientific Officer, then as Chief Strategy Officer, before becoming CEO. Prior to Siegfried, Dr. Wienand held senior management positions at Evonik Industries AG, a leading global specialty chemicals company. Dr. Wienand served as a non-executive board member for SCHOTT Pharma until December 2024.
- Pablo Perversi
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Michael A. Kelly
-
Michael A. Kelly， 自2008年7月起出任董事，并担任薪酬委员会委员。自2012年10月他担任3M公司电子和能源业务执行副总裁，之前自2006年10月他曾任该公司显示与图形执行副总裁。在此之前，自从他在1981年加入了3M，他曾在美国，新加坡韩国和德国担任多个管理职位。他曾在宾夕法尼亚大学沃顿商学院读完了行政教育。在他担任3M公司的电子和能源业务的执行副总裁期间，他要负责这价值60亿的全球业务所有运营和策略工作，包括3M的电子材料，电气市场，通信市场，电子解决方案，可再生能源，以及光学系统业务。
Michael A. Kelly,Retired Executive Vice President, Electronics and Energy Business of 3M Company, a diversified global technology company, from 2012 to 2016; he also served as Executive Vice President of the Display and Graphic Business from 2006 to 2012, and in various management positions in the U.S., Singapore, Korea and Germany. - Michael A. Kelly， 自2008年7月起出任董事，并担任薪酬委员会委员。自2012年10月他担任3M公司电子和能源业务执行副总裁，之前自2006年10月他曾任该公司显示与图形执行副总裁。在此之前，自从他在1981年加入了3M，他曾在美国，新加坡韩国和德国担任多个管理职位。他曾在宾夕法尼亚大学沃顿商学院读完了行政教育。在他担任3M公司的电子和能源业务的执行副总裁期间，他要负责这价值60亿的全球业务所有运营和策略工作，包括3M的电子材料，电气市场，通信市场，电子解决方案，可再生能源，以及光学系统业务。
- Michael A. Kelly,Retired Executive Vice President, Electronics and Energy Business of 3M Company, a diversified global technology company, from 2012 to 2016; he also served as Executive Vice President of the Display and Graphic Business from 2006 to 2012, and in various management positions in the U.S., Singapore, Korea and Germany.
- Thomas P. Salice
-
Thomas P. Salice，2005年1月至今为私募股权公司 SFW Capital Partners, LLC 的联合创始人兼管理成员。曾在私募股权公司 AEA Investors, Inc. 担任各种职务，包括董事总经理、总裁兼首席执行官和副主席（1989年6月至2004年12月）。几家私营公司的董事：Filtec and Gerson Lehrman Group, Inc. 和 Micromeritics Instrument Corporation。
Thomas P. Salice,has been a director since October 1996. He serves as Chair of the Compensation and Nominating & Corporate Governance Committees. He has a Master's in Business Administration from Harvard University. Mr. Salice is a co-founder, principal, and Managing Member of SFW Capital Partners, LLC. Mr. Salice was a Director of Waters Corporation until July 2022, and he is currently a Director of the privately-held companies Caron Products and Services Inc., Gerson Lehrman Group, Inc., Pion Inc., and RDI Technologies.Mr. Salice has been a Managing Member of SFW Capital Partners since January 2005. From June 1989 to December 2004, he served in a variety of capacities with AEA Investors, Inc., including Managing Director, President and Chief Executive Officer, and Vice-Chair. - Thomas P. Salice，2005年1月至今为私募股权公司 SFW Capital Partners, LLC 的联合创始人兼管理成员。曾在私募股权公司 AEA Investors, Inc. 担任各种职务，包括董事总经理、总裁兼首席执行官和副主席（1989年6月至2004年12月）。几家私营公司的董事：Filtec and Gerson Lehrman Group, Inc. 和 Micromeritics Instrument Corporation。
- Thomas P. Salice,has been a director since October 1996. He serves as Chair of the Compensation and Nominating & Corporate Governance Committees. He has a Master's in Business Administration from Harvard University. Mr. Salice is a co-founder, principal, and Managing Member of SFW Capital Partners, LLC. Mr. Salice was a Director of Waters Corporation until July 2022, and he is currently a Director of the privately-held companies Caron Products and Services Inc., Gerson Lehrman Group, Inc., Pion Inc., and RDI Technologies.Mr. Salice has been a Managing Member of SFW Capital Partners since January 2005. From June 1989 to December 2004, he served in a variety of capacities with AEA Investors, Inc., including Managing Director, President and Chief Executive Officer, and Vice-Chair.
- Brian Shepherd
-
Brian Shepherd从2005年10月到2009年3月担任产品管理部的部门副总裁，从2005年5月到2005年9月，担任产品管理部的高级副总裁，从2004年10月到2005年5月，担任技术营销部的高级副总裁。Shepherd先生于1996年加入PTC。
Brian Shepherd served as Divisional Vice President, Product Management from October 2005 to March 2009 as Senior Vice President, Product Management from May 2005 to September 2005 and as Senior Vice President, Technical Marketing from October 2004 to May 2005. Mr. Shepherd joined PTC in 1996. - Brian Shepherd从2005年10月到2009年3月担任产品管理部的部门副总裁，从2005年5月到2005年9月，担任产品管理部的高级副总裁，从2004年10月到2005年5月，担任技术营销部的高级副总裁。Shepherd先生于1996年加入PTC。
- Brian Shepherd served as Divisional Vice President, Product Management from October 2005 to March 2009 as Senior Vice President, Product Management from May 2005 to September 2005 and as Senior Vice President, Technical Marketing from October 2004 to May 2005. Mr. Shepherd joined PTC in 1996.
- Roland Diggelmann
-
Roland Diggelmann，自2022年8月起担任董事。他在审计委员会和薪酬委员会任职。他最近于2019年至2022年担任Smith & Nephew Plc首席执行官。在此之前，他曾于2012年至2018年担任Roche Diagnostics首席执行官，并于2008年至2012年担任亚太区董事总经理。在其职业生涯早期，Diggelmann曾在Zimmer Holdings、Centerpulse和Sulzer Medica担任多个高级管理职位。他是Sonova Holding AG的董事和提名与薪酬委员会成员，并且是瑞士公民。
Roland Diggelmann,served in various senior management roles at Zimmer Holdings, Centerpulse, and Sulzer Medica. He is a Director and serves as Chair of the Nomination and Compensation Committee at Sonova Holding AG, and is a Swiss citizen. - Roland Diggelmann，自2022年8月起担任董事。他在审计委员会和薪酬委员会任职。他最近于2019年至2022年担任Smith & Nephew Plc首席执行官。在此之前，他曾于2012年至2018年担任Roche Diagnostics首席执行官，并于2008年至2012年担任亚太区董事总经理。在其职业生涯早期，Diggelmann曾在Zimmer Holdings、Centerpulse和Sulzer Medica担任多个高级管理职位。他是Sonova Holding AG的董事和提名与薪酬委员会成员，并且是瑞士公民。
- Roland Diggelmann,served in various senior management roles at Zimmer Holdings, Centerpulse, and Sulzer Medica. He is a Director and serves as Chair of the Nomination and Compensation Committee at Sonova Holding AG, and is a Swiss citizen.
- Ingrid Zhang
-
Ingrid Zhang，自2023年2月起担任董事。她目前是Novartis创新药物中国区总裁。在担任这一职务之前，她曾在2017年至2022年期间担任Novartis制药中国区总裁，自2011年以来，她还在Novartis担任过多个领导职务，职责越来越多。在加入Novartis之前，Zhang女士曾在AstraZeneca、Pfizer和McKinsey & Company担任过多个高级管理职位。
Ingrid Zhang,has been a director since February 2023. She serves on the Nominating & Corporate Governance Committee. She is currently the Chief Commercial Officer, International, at Novartis. Prior to this role she was President and Managing Director of Novartis China from October 2023 to May 2024, President of China, Innovative Medicines at Novartis, from 2022 to October 2023, President Novartis Pharmaceuticals China from 2017 to 2022, and held several other leadership positions with increasing responsibilities at Novartis since 2011. Prior to Novartis, Ms. Zhang held various senior management roles with AstraZeneca, Pfizer, and McKinsey & Company. - Ingrid Zhang，自2023年2月起担任董事。她目前是Novartis创新药物中国区总裁。在担任这一职务之前，她曾在2017年至2022年期间担任Novartis制药中国区总裁，自2011年以来，她还在Novartis担任过多个领导职务，职责越来越多。在加入Novartis之前，Zhang女士曾在AstraZeneca、Pfizer和McKinsey & Company担任过多个高级管理职位。
- Ingrid Zhang,has been a director since February 2023. She serves on the Nominating & Corporate Governance Committee. She is currently the Chief Commercial Officer, International, at Novartis. Prior to this role she was President and Managing Director of Novartis China from October 2023 to May 2024, President of China, Innovative Medicines at Novartis, from 2022 to October 2023, President Novartis Pharmaceuticals China from 2017 to 2022, and held several other leadership positions with increasing responsibilities at Novartis since 2011. Prior to Novartis, Ms. Zhang held various senior management roles with AstraZeneca, Pfizer, and McKinsey & Company.
高管简历
中英对照 | 中文 | 英文- Patrick Kaltenbach
Patrick Kaltenbach于2021年1月加入Mettler-Toledo International Inc.，担任候任首席执行官，自2021年4月1日起担任首席执行官。在加入公司之前，他自2018年起担任Becton Dickinson生命科学部门的总裁。2014年至2018年，他担任安捷伦生命科学和应用市场集团总裁。此前，自1991年加入安捷伦及其前身惠普（Hewlett-Packard）以来，他在安捷伦（Agilent）担任了范围广泛且越来越多的领导职务。
Patrick Kaltenbach,joined the Company in January 2021 and assumed the role of Chief Executive Officer beginning April 1, 2021. Prior to joining the Company, he served as the President of the Life Sciences Segment at Becton Dickinson since 2018. He was President of Life Sciences and Applied Markets Group at Agilent from 2014 to 2018. Previously, he held wide-ranging and increasing leadership roles at Agilent and its predecessor company, Hewlett Packard, since joining in 1991.- Patrick Kaltenbach于2021年1月加入Mettler-Toledo International Inc.，担任候任首席执行官，自2021年4月1日起担任首席执行官。在加入公司之前，他自2018年起担任Becton Dickinson生命科学部门的总裁。2014年至2018年，他担任安捷伦生命科学和应用市场集团总裁。此前，自1991年加入安捷伦及其前身惠普（Hewlett-Packard）以来，他在安捷伦（Agilent）担任了范围广泛且越来越多的领导职务。
- Patrick Kaltenbach,joined the Company in January 2021 and assumed the role of Chief Executive Officer beginning April 1, 2021. Prior to joining the Company, he served as the President of the Life Sciences Segment at Becton Dickinson since 2018. He was President of Life Sciences and Applied Markets Group at Agilent from 2014 to 2018. Previously, he held wide-ranging and increasing leadership roles at Agilent and its predecessor company, Hewlett Packard, since joining in 1991.
- Shawn P. Vadala
Shawn P. Vadala，他于1997年加入公司，并一直担任首席财务官（2004年1月以来）。他负责公司的定价和商业智能项目。他此前曾担任公司的俄亥俄州哥伦布、瑞士格里芬湖办公室的多种高级财务职务。加入公司之前，他曾任职PricewaterhouseCoopers公司的波士顿和瑞士、苏黎世办事处。
Shawn P. Vadala,joined the Company in 1997 and has been Chief Financial Officer since January 2014 and also responsible for the Company's Pricing program since 2008. Mr. Vadala previously held various senior financial positions at the Company's Columbus, Ohio and Greifensee, Switzerland offices and was also responsible for Business Intelligence from 2010 to 2018. Prior to joining the Company, he worked in the Boston and Zurich, Switzerland offices of PricewaterhouseCoopers.- Shawn P. Vadala，他于1997年加入公司，并一直担任首席财务官（2004年1月以来）。他负责公司的定价和商业智能项目。他此前曾担任公司的俄亥俄州哥伦布、瑞士格里芬湖办公室的多种高级财务职务。加入公司之前，他曾任职PricewaterhouseCoopers公司的波士顿和瑞士、苏黎世办事处。
- Shawn P. Vadala,joined the Company in 1997 and has been Chief Financial Officer since January 2014 and also responsible for the Company's Pricing program since 2008. Mr. Vadala previously held various senior financial positions at the Company's Columbus, Ohio and Greifensee, Switzerland offices and was also responsible for Business Intelligence from 2010 to 2018. Prior to joining the Company, he worked in the Boston and Zurich, Switzerland offices of PricewaterhouseCoopers.
- Gerhard Keller
Gerhard Keller，1991年加入公司，自2018年7月起担任过程分析主管，自2013年7月起担任移液器主管。他此前担任东亚/太平洋区域主管，还曾在欧洲和亚太地区担任多个销售和营销领导职能。在加入公司之前，他曾在瑞士的Sandoz（现为诺华）从事质量控制工作。
Gerhard Keller,joined the Company in 1991 and has been Head of Process Analytics since July 2018 and Head of Pipettes since July 2013. He previously was Head of Region East Asia/Pacific and also served in various Sales and Marketing leadership functions in Europe and Asia Pacific. Prior to joining the Company, he worked in Quality Control at Sandoz, now Novartis, in Switzerland.- Gerhard Keller，1991年加入公司，自2018年7月起担任过程分析主管，自2013年7月起担任移液器主管。他此前担任东亚/太平洋区域主管，还曾在欧洲和亚太地区担任多个销售和营销领导职能。在加入公司之前，他曾在瑞士的Sandoz（现为诺华）从事质量控制工作。
- Gerhard Keller,joined the Company in 1991 and has been Head of Process Analytics since July 2018 and Head of Pipettes since July 2013. He previously was Head of Region East Asia/Pacific and also served in various Sales and Marketing leadership functions in Europe and Asia Pacific. Prior to joining the Company, he worked in Quality Control at Sandoz, now Novartis, in Switzerland.
- Richard Wong
Richard Wong自2009年起担任亚太市场组织负责人。在2008年加入公司之前，他曾于1998年至2008年在安捷伦科技公司担任过多个区域管理职位，包括总部位于北京和东京的北亚生命科学现场运营。1991年，他在惠普公司开始了他的职业生涯，并在销售与市场营销和财务部门担任了越来越多的职务。
Richard Wong,has been Head of Asia/Pacific since 2009. Prior to joining the Company in 2008, he held various regional management positions with Agilent Technologies from 1998 to 2008 including Life Sciences Field Operations for North Asia based in Beijing and later in Tokyo. He started his career with Hewlett Packard in 1991 and held positions of increasing responsibilities in Sales and Marketing and Finance.- Richard Wong自2009年起担任亚太市场组织负责人。在2008年加入公司之前，他曾于1998年至2008年在安捷伦科技公司担任过多个区域管理职位，包括总部位于北京和东京的北亚生命科学现场运营。1991年，他在惠普公司开始了他的职业生涯，并在销售与市场营销和财务部门担任了越来越多的职务。
- Richard Wong,has been Head of Asia/Pacific since 2009. Prior to joining the Company in 2008, he held various regional management positions with Agilent Technologies from 1998 to 2008 including Life Sciences Field Operations for North Asia based in Beijing and later in Tokyo. He started his career with Hewlett Packard in 1991 and held positions of increasing responsibilities in Sales and Marketing and Finance.
- Marc de la Gueronniere
Marc de la Gueronniere，自2008年1月起担任公司欧洲市场组织主管，自2014年4月起担任北美市场组织主管。他曾于2006年1月至2008年1月担任区域南部主管和公司在西班牙的市场组织总经理。2001年加入公司，担任法国梅特勒-托利多 International TERM0 Inc.市场组织工业业务区域经理。在加入之前，Marc de la Gueronniere先生曾在ABB-Elsag Bailey和Danaher-Zellweger担任欧洲和美国的多个管理职位。
Marc de la Gueronniere,has been Head of European Market Organizations of the Company since January 2008 and Head of North American Market Organizations since April 2014. He was Head of Region South and General Manager of the Company's market organization in Spain from January 2006 to January 2008. He joined the Company in 2001 as the Industrial Business Area Manager for Mettler-Toledo International Inc. market organization in France. Prior to joining the Company, Mr. de La Guéronnière held various management positions in Europe and the United States with ABB-Elsag Bailey and Danaher-Zellweger.- Marc de la Gueronniere，自2008年1月起担任公司欧洲市场组织主管，自2014年4月起担任北美市场组织主管。他曾于2006年1月至2008年1月担任区域南部主管和公司在西班牙的市场组织总经理。2001年加入公司，担任法国梅特勒-托利多 International TERM0 Inc.市场组织工业业务区域经理。在加入之前，Marc de la Gueronniere先生曾在ABB-Elsag Bailey和Danaher-Zellweger担任欧洲和美国的多个管理职位。
- Marc de la Gueronniere,has been Head of European Market Organizations of the Company since January 2008 and Head of North American Market Organizations since April 2014. He was Head of Region South and General Manager of the Company's market organization in Spain from January 2006 to January 2008. He joined the Company in 2001 as the Industrial Business Area Manager for Mettler-Toledo International Inc. market organization in France. Prior to joining the Company, Mr. de La Guéronnière held various management positions in Europe and the United States with ABB-Elsag Bailey and Danaher-Zellweger.
- Christian Magloth
Christian Magloth，于2010年10月加入该公司；自2010年12月以来，一直是人力资源主管。在加入该公司之前，他曾于2006年4月-2010年9月期间，在一家瑞士证券交易所（Swiss stock exchange）上市的大型全球医疗设备公司- Straumann，担任人力资源总监。他此前曾在一家国际消费食品公司- Hero Group担任人力资源总监，以及在一家大型全球建筑供应公司- Hilti担任各种管理职位。
Christian Magloth,joined the Company in October 2010 and has been Head of Human Resources since December 2010. Prior to joining the Company, he served as Head of Human Resources of Straumann, a leading global medical devices company listed on the Swiss stock exchange, from April 2006 to September 2010. He previously served as Head of Human Resources at Hero Group, an international consumer foods company, and in various management positions at Hilti, a leading global construction supply company.- Christian Magloth，于2010年10月加入该公司；自2010年12月以来，一直是人力资源主管。在加入该公司之前，他曾于2006年4月-2010年9月期间，在一家瑞士证券交易所（Swiss stock exchange）上市的大型全球医疗设备公司- Straumann，担任人力资源总监。他此前曾在一家国际消费食品公司- Hero Group担任人力资源总监，以及在一家大型全球建筑供应公司- Hilti担任各种管理职位。
- Christian Magloth,joined the Company in October 2010 and has been Head of Human Resources since December 2010. Prior to joining the Company, he served as Head of Human Resources of Straumann, a leading global medical devices company listed on the Swiss stock exchange, from April 2006 to September 2010. He previously served as Head of Human Resources at Hero Group, an international consumer foods company, and in various management positions at Hilti, a leading global construction supply company.
- Roland Diggelmann
Roland Diggelmann，自2022年8月起担任董事。他在审计委员会和薪酬委员会任职。他最近于2019年至2022年担任Smith & Nephew Plc首席执行官。在此之前，他曾于2012年至2018年担任Roche Diagnostics首席执行官，并于2008年至2012年担任亚太区董事总经理。在其职业生涯早期，Diggelmann曾在Zimmer Holdings、Centerpulse和Sulzer Medica担任多个高级管理职位。他是Sonova Holding AG的董事和提名与薪酬委员会成员，并且是瑞士公民。
Roland Diggelmann,served in various senior management roles at Zimmer Holdings, Centerpulse, and Sulzer Medica. He is a Director and serves as Chair of the Nomination and Compensation Committee at Sonova Holding AG, and is a Swiss citizen.- Roland Diggelmann，自2022年8月起担任董事。他在审计委员会和薪酬委员会任职。他最近于2019年至2022年担任Smith & Nephew Plc首席执行官。在此之前，他曾于2012年至2018年担任Roche Diagnostics首席执行官，并于2008年至2012年担任亚太区董事总经理。在其职业生涯早期，Diggelmann曾在Zimmer Holdings、Centerpulse和Sulzer Medica担任多个高级管理职位。他是Sonova Holding AG的董事和提名与薪酬委员会成员，并且是瑞士公民。
- Roland Diggelmann,served in various senior management roles at Zimmer Holdings, Centerpulse, and Sulzer Medica. He is a Director and serves as Chair of the Nomination and Compensation Committee at Sonova Holding AG, and is a Swiss citizen.